Caribou Biosciences (CRBU) Financials: History & Chart

Caribou Biosciences, Inc.(CRBU)

Biotechnology · Berkeley, CA

$1.16-0.03 (-2.52%)

Delayed quote: Oct 6, 2026, 1:45 PM EDT

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

Berkeley, CA

97 employees

cariboubio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Rachel E. Haurwitz

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	10.04M	1.50M	2.40M	3.94M	2.20M	2.67M	2.35M	2.08M	2.02M
Cost of Goods Sold	23.05M	0.00	649K	0.00	22.40M	1.30M	1.74M	29.86M	29.82M
Gross Profit	-13.02M	1.50M	1.75M	3.94M	-20.20M	1.37M	610K	-27.79M	-27.80M
Gross Profit Margin	-129.7%	100.0%	72.9%	100.0%	-919.2%	51.3%	25.9%	-1337.8%	-1373.4%
Total Operating Expenses	96.46M	26.84M	28.03M	32.39M	9.20M	48.95M	43.52M	11.09M	10.44M
Research & Development	85.77M	18.94M	20.61M	23.82M	22.40M	27.69M	35.53M	30.46M	30.42M
Selling, General & Administrative	33.74M	7.90M	8.07M	8.58M	9.20M	10.40M	9.73M	10.49M	5.94M
Operating Income (EBIT)	-109.47M	-25.34M	-26.28M	-28.45M	-29.40M	-47.58M	-42.91M	-38.88M	-38.24M
Operating Margin	-1090.9%	-1690.4%	-1096.4%	-722.0%	-1337.6%	-1784.0%	-1823.8%	-1871.7%	-1889.2%
Income Before Tax (EBT)	-103.95M	-24.28M	-25.09M	-27.04M	-27.55M	-54.10M	-39.99M	-35.50M	-34.68M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	5.52M	1.06M	1.20M	1.42M	1.85M	-6.52M	2.92M	3.38M	3.55M
Net Income	-103.40M	-24.28M	-25.09M	-26.49M	-27.55M	-54.10M	-39.99M	-35.49M	-34.68M
Income Tax Expense	-550K	0.00	0.00	-550K	0.00	0.00	0.00	-9K	0.00
Net Profit Margin	-1030.4%	-1619.9%	-1046.5%	-672.1%	-1253.3%	-2028.4%	-1699.6%	-1708.7%	-1713.6%
EBITDA	-106.89M	-24.71M	-25.63M	-27.77M	-28.77M	-46.41M	-41.75M	-37.69M	-37.06M
EBITDA Margin	-1065.1%	-1648.7%	-1069.3%	-704.7%	-1308.9%	-1740.2%	-1774.2%	-1814.7%	-1831.1%
Depreciation & Amortization	2.59M	625K	649K	682K	631K	1.17M	1.17M	1.18M	1.18M
EPS Basic	-1.08	-0.24	-0.26	-0.28	-0.30	-0.58	-0.43	-0.39	-0.38
EPS Diluted	-1.08	-0.24	-0.26	-0.28	-0.30	-0.58	-0.43	-0.39	-0.38
Weighted Average Basic Shares	100.99M	100.99M	95.86M	94.54M	93.29M	93.03M	92.68M	90.32M	90.46M
Weighted Average Diluted Shares	100.99M	100.99M	95.86M	94.54M	93.29M	93.03M	92.68M	90.32M	90.46M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	11.16M	9.99M	34.48M	13.85M	9.60M	12.36M	5.79M
Cost of Goods Sold	3.65M	3.93M	3.52M	3.64M	984K	34.42M	0.00
Gross Profit	7.51M	6.07M	30.95M	10.21M	8.61M	-22.06M	5.79M
Gross Profit Margin	67.3%	60.7%	89.8%	73.7%	89.7%	-178.5%	100.0%
Total Operating Expenses	143.71M	172.68M	147.01M	116.61M	75.59M	14.06M	40.09M
Research & Development	109.44M	130.15M	112.08M	82.23M	52.26M	34.42M	23.64M
Selling, General & Administrative	37.91M	46.46M	38.46M	38.02M	23.34M	14.06M	16.46M
Operating Income (EBIT)	-136.19M	-166.62M	-116.06M	-106.40M	-66.98M	-36.12M	-34.30M
Operating Margin	-1220.5%	-1667.2%	-336.6%	-768.2%	-697.8%	-292.2%	-592.7%
Income Before Tax (EBT)	-148.68M	-149.11M	-101.88M	-99.35M	-66.60M	-36.13M	-30.97M
Interest Income	8.00M	N/A	10.70M	4.60M	148K	236K	1.05M
Interest Expense	N/A	N/A	N/A	N/A	8K	20K	4K
Other Income/Expense	-12.48M	17.50M	14.18M	7.05M	377K	-3K	3.34M
Net Income	-148.13M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M	-23.43M
Income Tax Expense	-550K	-9K	193K	70K	321K	-1.82M	-7.54M
Net Profit Margin	-1327.4%	-1491.9%	-296.1%	-717.8%	-697.3%	-277.6%	-404.8%
EBITDA	-132.55M	-162.69M	-112.53M	-102.76M	-66.00M	-35.22M	-33.55M
EBITDA Margin	-1187.8%	-1627.9%	-326.4%	-741.9%	-687.6%	-285.0%	-579.7%
Depreciation & Amortization	3.65M	3.93M	3.52M	3.64M	984K	900K	751K
EPS Basic	-1.59	-1.65	-1.38	-1.64	-1.11	-1.24	-0.85
EPS Diluted	-1.59	-1.65	-1.38	-1.64	-1.11	-1.24	-0.85
Weighted Average Basic Shares	93.39M	90.32M	73.81M	60.80M	60.26M	27.66M	27.66M
Weighted Average Diluted Shares	93.39M	90.32M	73.81M	60.80M	60.26M	27.66M	27.66M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.